Fabrice Lejeune, a researcher at the UMR 8161 M3T Mechanisms of Tumorigenesis and Target Therapies laboratory (University of Lille, CNRS and Pasteur Institute of Lille), supported by the Rare Disease Foundation, has just developed a test system in cells to identify new molecules to correct non-sense mutations.